Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining capecitabine, paclitaxel, and trastuzumab in treating patients who have metastatic breast cancer.

Key facts

Study ID

NCT00006108

Run by

UNC Lineberger Comprehensive Cancer Center

Starts

1999-08-01

Expected to finish

2002-07-01

Last updated by the study team

2012-02-07

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.